Clinical Trials Directory

Trials / Completed

CompletedNCT03545243

PPI and Microbiome in Healthy Volunteers and Functional Dyspepsia

Effect of Proton Pump Inhibitors on the Duodenal Microbiome in Healthy Volunteers and Functional Dyspepsia Patients

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
79 (actual)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Academic / Other
Sex
All
Age
18 Years – 64 Years
Healthy volunteers
Accepted

Summary

Prospective interventional study of the effect of PPI on the duodenal microbiome in healthy volunteers and functional dyspepsia patients

Detailed description

PPIs are the first-line therapy in functional dyspepsia (FD) but frequently (over-)prescribed with potential adverse events, especially in the long term. As C. difficile and CAP are important causes of morbidity, mortality and healthcare costs, it is important to study the underlying mechanisms of PPI-induced dysbiosis. In this prospective interventional study, study procedures will be performed at inclusion (1), after a baseline period of 4 weeks (2) and after treatment with Pantoprazole (Pantomed®) 40mg once daily during 4 weeks (3) in healthy volunteers and FD patients. In addition, study procedures will be performed at inclusion (1) and after PPI-withdrawal for 8 weeks in refractory FD patients. The investigators aim to assess alterations of the duodenal (mucosa-associated and luminal) microbiome with PPI therapy and to correlate changes in the duodenal microbiota with oral and fecal microbiota, bile acids, intestinal permeability and histology and biochemical variables. The results from this study will help to unravel the onset and extent of dysbiosis and provide additional arguments not to prescribe or continue PPI without clear clinical indications, especially in cases where alternative regimens may be available or the benefits of PPI are uncertain.

Conditions

Interventions

TypeNameDescription
DRUGPantoprazole 40mgPeroral Pantoprazole 40mg once daily during 28 days
OTHERPPI withdrawalPPI withdrawal for 8 weeks

Timeline

Start date
2018-04-23
Primary completion
2020-03-08
Completion
2020-09-22
First posted
2018-06-04
Last updated
2020-09-28

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT03545243. Inclusion in this directory is not an endorsement.